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ABSTRACT 
The glycosphingolipidosis Gaucher disease, in which a range of neurological 
manifestations occur, results from a deficiency of acid β-glucocerebrosidase, with 
subsequent accumulation of β-glucocerebroside, its upstream substrates and the 
unacylated congener, ß-glucosylsphingosine. However, the mechanisms by which end-
organ dysfunction arise are poorly understood. Here we report strikingly diminished 
cerebral microvascular density in a murine model of disease and provide a detailed 
analysis of the accompanying cerebral glycosphingolipidome in these animals, with 
marked elevations of ß-glucosylsphingosine. Further in vitro studies confirm a 
concentration dependent impairment of endothelial cytokinesis upon exposure to quasi-
pathological concentrations of ß-glucosylsphingosine. These findings support a premise 
for pathogenic disruption of cerebral angiogenesis as an end-organ effect, with potential 
for therapeutic modulation in neuronopathic Gaucher disease. 
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INTRODUCTION 
Disorders of glycosphingolipid metabolism, such as Gaucher disease, are important 
causes of inherited neurodegeneration. The heterogeneous glycosphingolipidosis, 
Gaucher disease, in which diverse neurological manifestations occur, is due to deficiency 
of acid β-glucocerebrosidase, which leads to impaired lysosomal recycling of 
glucosylceramide accompanied by accumulation its unacylated congener, ß-
glucosylsphingosine. 
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While disordered glycosphingolipid homeostasis is a primary feature of Gaucher disease, 
the mechanisms by which end-organ dysfunction and injury arise, particularly in the 
brain, are little understood. 
In the biochemically related glycosphingolipid disease, globoid-cell leukodystrophy, 
(Krabbe disease) marked disturbances of cerebral angiogenesis are reported [1,2]; these 
authors provided compelling evidence that implicates the pathological accumulation of 
the cognate lysolipid, ß-galactosylsphingosine in its neuropathogenesis [1-3]. The 
complexity of glycosphingolipid control in the formation of vascular networks by higher-
order gangliosides is well recognised [4-6] and, given the perturbation of these molecules 
in Gaucher disease [7-11], the potential for consequent disruption of cerebral 
angiogenesis merits further exploration. Since the two lysosphingolipids, ß-
galactosylsphingosine and ß-glucosylsphingosine are closely related molecules, known 
collectively as ‘psychosine’, a common mechanism might also explain the ontogeny of 
acute neuronopathic Gaucher disease. Other striking shared pathological features of these 
diseases include the presence of large multi-nucleate tissue macrophages - the eponymous 
Gaucher cell and globoid cell in Gaucher and Krabbe disease respectively. It is notable 
also that exposure of cultured human macrophage-like cells to psychosines arrests 
cytokinesis and induces a Gaucher-like cell phenotype [12,13].  
 Here we report strikingly diminished cerebral microvascular density in an authentic and 
genetically coherent model of acute neuronopathic Gaucher disease generated in mice 
[14]; we further provide a detailed analysis of the accompanying cerebral 
glycosphingolipidome of these animals. Experimental studies using cultured primary 
human umbilical vein endothelial cells showed concentration-dependent impairment of 
endothelial cytokinesis after exposure to quasi-pathological concentrations of ß-
glucosylsphingosine.  
In summary, we provide experimental evidence that the pathological glycosphingolipids 
which accumulate specifically in Gaucher disease, markedly disrupt cerebral 
microvasculature in a context that is likely to contribute materially to the severe 
neurological manifestations of this glycosphinglipidosis. Since several advanced 
molecular therapies are in late-stage development for neuronopathic Gaucher disease, we 
contend that due weight should be paid to a relationship between our findings and a 
putative effect of Gaucher disease on angiogenesis and formation of the fully ramified 
microvascular network in the mature brain.  
MATERIALS AND METHODS 
Animal model 
The conditional mouse model of acute neurological Gaucher disease (nGD) (K-14Cre-
positive gbalnl/lnl) employed in these experiments is well-characterised, and develops an 
acute neuronopathic phenotype resembling the severe human disease subtype, type 2 
Gaucher disease, 14]. Experimental homozygotes at mutant gba locus and paired, gender-
matched, littermate control animals were harvested on post-natal day (PND) 14 for 
analysis. This work was performed under United Kingdom Home Office licence (PPL 
80/2109) in accordance with the Animals (Scientific Procedures) Act 1986 and regulated 
by the institutional animal welfare and scientific procedure guidelines. 
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Quantification of neocortical and thalamic cerebral microvasculature vessel length 
volume density 
Animals were terminally anaesthetised by intraperitoneal injection of 20% sodium 
pentobarbital, exsanguinated and transcardially perfused under manual pressure via 60 
mL Luer-lock syringe; first-phase perfusion was performed with India ink, diluted in PBS 
at a dilution ratio of ink:PBS = 1:1, followed by a second perfusion with India ink diluted 
in 4% paraformaldehyde in PBS, at a dilution ratio of ink:paraformaldehyde = 0.5:1.  
Whole brains were removed and post-fixed by immersion in 4% w/v paraformaldehyde for 
72 hours. Serial coronal sections (30µm) were cut, slide mounted and counter stained 
(cresyl violet 0.5%) for analysis.  
Quantification of vessel length-volume density (Lvd) was carried out in preselected 
anatomical regions of interest: i) the neocortex and ii) the thalamus. Non-contiguous 
sections at 120µm intervals in the coronal axis were selected at three sampling regions 
from the neocortex and two regions within the thalamus, over bilateral hemispheres to 
yield a total of 18 (neocortical) and 12 (thalamic) sampling fields per animal. Selected 
fields were imaged by bright field microscopy at 4x objective magnification; digital 
images were captured for off-line analysis using ImageJ software (U. S. National 
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012). 
These analyses were conducted by an operator blinded in respect of the experimental 
group from which the tissue was obtained. Selected fields were overlaid with a gridded 
sampling probe (300 x 300µm per frame) and total vessel length was averaged over 3 
frames per field, selected by systematic random sampling. Measurements were conducted 
in 2-dimensional reference using the ImageJ segmental tracing tool; aggregate 
measurements were expressed as an average linear density per μm3 (accounting for the 30 
μm depth of the tissue section). Difference in mean values was compared by two-tailed 
Student’s t-test (α = 0.05) with assumed homoscedastic variance. 
Quantification of multinucleated cells in ß-glucosylsphingosine-treated human 
umbilical vein endothelial cell monolayers 
Primary human umbilical vein endothelial cells (HUVECs) (Health Protection Agency) 
were cultured in EBM-2 basal medium + EGM™-2MV BulletKit™ (Lonza). All 
experiments utilised asynchronous primary cultures, harvested from a common passage. 
Untreated cells were plated on borosilicate coverslips in 6-well plates, at a uniform 
density of 0.5 x 105 cells per well for 24 hours; at which point, exchange with ß-
glucosylsphingosine (D-Glucosyl-β1-1'-D-erythro-Sphingosine) (Avanti Polar Lipids) 
containing medium at 0µM (vehicle only control), 5µM and 10µM concentrations was 
undertaken. All treatments were conducted in triplicate and 3 experimental replicates 
were carried out on separate occasions. Monolayers were harvested at 24 and 48 hours’ 
post treatment and fixed in 4% paraformaldehyde for analysis. Monolayers were stained 
with tetramethylrhodamine isothiocyanate conjugated phalloidin (Invitrogen), at a 
concentration of 6.25µg/ml for 45 minutes at room temperature and mounted with anti-
fade mounting agent containing 4',6-diamidino-2-phenylindole (Prolong Gold®). Laser 
scanning confocal microscopy (Leica SP-5 LSCM) was performed at 10x objective 
magnification for quantification of percentage multinucleated cells per unit area. 
Randomly selected images were digitally captured for off-line analysis, conducted blind 
to treatment effect; images were overlaid with a 1550µm x 1550µm sampling probe and 
count strategies employed the stereological principle of the ‘dead-side’ rule, with 
exclusion of cells falling within the sampling frame if intersected by either of the 
‘excluded’ perpendicular borders. Mononucleated, binucleated and multinucleated (≥ 3 
nuclei) cells were quantified as a percentage of total cells within the sampling frame. In 
each experiment a total of three sampling frames were analyzed per treatment 
concentration. One-way analysis of variance (α = 0.05) with a Bonferroni post hoc 
analysis was employed for comparison of percentage count by treatment concentration.  
Quantitative analysis of monolayer wound closure in glucosylsphingosine treated 
human umbilical vein endothelial cell monolayers 
Asynchronous HUVEC cultures were used for wound healing assays. After obtaining 
these cells as described above, monolayers were plated at uniform density and grown to 
confluence in 24-well tissue culture plates, pre-marked with scored reference grids. 
Linear wounds were manually inflicted along the diameter of the well using a sterile p20 
pipette tip, cellular debris removed and fresh culture medium with containing serially 
increasing concentrations of ß-glucosylsphingosine applied at 0µM (vehicle only 
control), 0.6µM, 1.25µM, 2.5µM, 5µM, 10µM and 15µM. A minimum of three replicate 
wound assays were performed per experiment. Wounds were serially imaged at 0 hours, 8 
hours, 20 hours, and 40 hours, to the point of wound closure. Parallel experiments were 
carried out after inhibiting endogenous β-glucocerebrosidase by exposure to the 
irreversible and selective suicide inhibitor, cyclophellitol (2.5µg /ml), effecting near total 
inhibition of acid β-glucocerebrosidase activity (data not shown). Serial measurements of 
wound width (relative to fixed reference markings) were averaged over three 
measurements per time point.  Each treatment was carried out in triplicate and expressed 
as mean percentage wound closure; complete closure was assigned to the a ceiling effect 
at the first time point achieved. Statistical comparison of mean percentage closure with 
respect to ß-glucosylsphingosine concentration was assessed by 2-way analysis of 
variance (α = 0.05) using the Bonferroni post hoc correction and assuming homoscedastic 
variance.  
Lipidomic analysis of brain regions 
Animals were terminally anaesthetised (as previously described), exsanguinated and their 
whole brains dissected from the skull; the neocortex and subcortex were anatomically 
dissected, snap frozen in liquid nitrogen and stored at -80oC for lipid analysis. Each brain 
region was resuspended in 0.02 M Tris (pH 7) containing 0.5 M NaCl and 0.1% Nonidet 
P-40 (10X volume per weight) and homogenised on ice in a 4.5 mL glass Dounce 
homogeniser.  Total protein was determined by the method of Lowry et al. (1957) and 
0.01 mL of 5 µg/µL and 10 µg/µL was extracted for sphingolipids and gangliosides 
respectively, with the addition of 0.2 mL of CHCl3:CH3OH (2:1) containing 5 pmol of 
dihydroceramide (dhCer) d18:0/8:0 {N-octanoyl-D-erythro-sphinganine}, sphingomyelin 
(SM) d18:1/12:0 {N-lauroyl-D-erythro-sphingosylphosphorylcholine}, 10 pmol of 
ceramide (Cer) d18:1/17:0 {N-heptadecanoyl-D-erythro-sphingosine},  
dihexosylceramide (DHC) d18:1/16:0 (d3) {N-palmitoyl-d3-lactosylceramide}, 
monohexosylceramide (MHC) d18:1/16:0 (d3) {N-palmitoyl-d3-glucopsychosine} 
trihexosylceramide (THC) d18:1/17:0 {N-heptadecanoyl ceramide trihexoside}, GM1 
d18:1/18:0 (d3) {(N-omega Cd3-octadecanoyl monosialoganglioside GM1 d18:1/18:0 
(ammonium salt)} and 1 nmol of cholesterol (d7) as internal standards (Standards 
purchased from Avanti Polar Lipids, with the exception of DHC, MHC, THC and GM1 
from Matreya LLC).  After brief agitation in Vortex mixer, samples were mixed on a 
rotary mixer for 10 mins, sonicated in a water bath for 30 mins and then allowed to stand 
at room temperature for 20 mins.  The protein was sedimented by centrifugation at 
13,000g for 10 mins at RT, the supernatant removed and dried under a gentle stream of 
nitrogen at 40oC.  Samples were stored at -20 oC until LC-ESI-MS/MS analysis. 
The lipid extract was reconstituted in 0.1 mL of CH3OH containing 10 mM NH4COOH 
and for all lipids, except gangliosides, 1 µl was injected onto a Zorbax Eclipse C18, 2.1 
mm x 50 mm column maintained at 40oC (CTO-30A oven) using a Shimadzu Nexera x2 
SIL-30AC autosampler maintained at 16oC configured with LC 30 AD pumps.  A 1290 
inline filter containing a 0.3 µm frit was placed in front of the column.  Solvent A was 
60% H2O, 40% CH3CN containing 10 mM NH4COOH and solvent B was 90% 
(CH3)2CHOH, 10% CH3CN containing 10 mM NH4COOH.  At injection, mobile phase 
conditions were 90% solvent A and 10% solvent B, which was linearly ramped to 50% 
by 2 mins and then to 100% solvent B at 8.0 mins.  This was held for 0.5 mins followed 
by a return to 90% solvent A at 9 mins, which was equilibrated for 1 min prior to the next 
injection.  The flow rate was 0.4 mL/min.  
For the first minute column flow was diverted to waste and then directly into the 
electrospray source (ES 5500 V) of an AB SCIEX 6500 QTrap triple quadrupole tandem 
mass spectrometer with an ion source temperature of 250oC.  Nitrogen was used for 
curtain gas, 25 units; collision gas set at medium; nebuliser gas 1, 20 units and auxillary 
gas 2, 45 units.  Individual species of dhCer, Cer, DHC, MHC, THC and sulphatides, as 
well as the single species, glucosylsphingosine were quantified using scheduled multiple 
reaction monitoring (MRM) in positive ion mode (see Supplementary Table 1).  
Concentrations of each molecular species were calculated by relating the peak areas of 
each species to the peak area of the corresponding internal standard using MultiQuant 
3.0.2 software.  For sulphatides and glucosylsphingosine, THC d18:1/17:0 and DHC 
d18:1/16:0 d3, respectively, were used. 
Individual species of gangliosides were quantified in a separate acquisition method in 
negative ion mode (ES -4500) with a less precipitous LC gradient.  Mobile phase A and B 
were as described above except 0.05% NH4OH replaced NH4COOH to ensure the larger 
gangliosides (MW > 1000) could be quantified as doubly charged ions. At injection, 
mobile phase conditions were 90% solvent A and 10% solvent B, which was linearly 
ramped to 30% B by 5 mins, 60 % B by 8 mins and then to 100% B at 10.5 mins.  This 
was held for 0.5 mins followed by a return to 10% B at 11 mins, which was equilibrated 
for 1 min prior to the next injection.  Individual species of gangliosides were quantified 
using non-scheduled MRM and concentrations were calculated by relating the peak areas 
of each species to the peak area of GM1 18:1/18:0 (d3) using MultiQuant 3.0.2 software.   
Results are presented as the mean ± SEM with four nGD and four WT mice each assayed 
in triplicate. Differences between nGD and WT were analysed for significance using a 
two-tailed Student’s t-test following an F-test for homoscedastic variance.  Pearson’s 
correlation coefficients between individual lipid species and the three brain regions were 
also determined using SPSS version 15.0 for Windows statistics software. 
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RESULTS 
Quantification of neocortical and thalamic cerebral microvasculature vessel length 
volume density 
Matched disease (n=3) and control (n=3) animals were included for quantification of 
vessel length volume density (Lvd) within the neocortex and thalamus (cerebellar vascular 
density was not assessed). Regional analysis revealed a statistically significant reduction 
in mean Lvd within both the neocortex (p = 0.0220) and thalamus (p = 0.0222) of diseased 
relative to age and gender matched control animals; a trend that proved consistent within 
individual animals [Figure 1]. Mean neocortical Lvd (± SEM) measured 5.44 ± 0.12 x10-4 
µm/µm3 and 4.36 ± 0.27 x10-4 µm/µm3 and mean thalamic Lvd measured 5.26 ± 0.23 x10-
4 µm/µm3 and 4.13 ± 0.21 x10-4 µm/µm3 in control and diseased cohorts respectively. No 
significant difference was noted between subregions within each group. 
Analysis of multinucleated cells in ß-glucosylsphingosine-treated human umbilical 
vein endothelial cell monolayers 
Quantitative analysis of percentage multinucleate cell count, relative to 
glucosylsphingosine at quasi-pathological treatment concentrations was undertaken in 
human umbilical vein endothelial cell monolayers (HUVEC monolayers); three replicate 
experiments were performed, with analysis at 24 hour and 48 hour culture duration 
[Supplementary figure 1]. Mean percentage cell counts demonstrated increased 
binucleated (p = 0.0416) and multinucleated (p = 0.0281) percentages of total cell count 
in 5µM and 10µM treated monolayers, relative to vehicle only controls; post hoc 
Bonferroni analysis did not demonstrate individual comparator significance for 
binucleated percentage counts, while multinucleated cell percentages were significantly 
greater at 5µM relative to untreated monolayers. This trend was reinforced at 48 hour 
analysis, with both binucleated (p = 0.0008) and multinucleated (p = 0.0040) cell 
percentages significantly increased following 5µM and 10µM glucosylsphingosine 
treatment; in both cases Bonferroni analysis confirmed significant increases relative to 
untreated monolayers, although increased effect with doubling of concentration (5µM vs 
10µM) was not observed.  
Quantitative analysis of monolayer wound closure in ß-glucosylsphingosine- and 
cyclophellitol-treated human umbilical vein endothelial cell monolayers 
Wound healing assays (n=6) demonstrated a statistically significant reduction in mean 
percentage wound closure, relative to treatment concentration (Pinteraction = 0.0194; PGlcSph 
concentration  < 0.0001; Ptime < 0.0001). Post-hoc Bonferroni comparison confirmed 
significant effects for treatment concentrations ≥ 1.25µM glucosylsphingosine treatment 
(i.e. ≥ 1.25µM) at the 8 hour time point and from 10µM concentration for the remaining 
time points – reflecting ceiling wound closure of HUVEC monolayers in the majority of 
replicate experiments prior to the 20 hour time point. [Supplementary figure 2a]. 
Replicate experiments (n=3) utilizing monolayers pretreated with the irreversible β-
glucocerebrosidase inhibitor, cyclophellitol, demonstrated treatment effects congruent 
with enzyme replete cultures; concentration dependent delays in mean percentage wound 
closure were recorded in ß-glucosylsphingosine-treated monolayers (n=3) (Pinteraction < 
0.0001; PGlcSph concentration  < 0.0001; Ptime < 0.0001). As expected, greater sensitivity to 
exogenous ß-glucosylsphingosine was apparent when post-hoc Bonferonni analysis was 
carried out, with significant retardation of wound closure upon application of 0.6µM ß-
glucosylsphingosine (the lowest treatment concentration applied) compared to 1.25µM 
retardation in uninhibited cultures [Supplementary figure 2b]. 
Regional brain lipidomic analysis 
Beta-glucosylsphingosine and total monohexosylceramide (MHC) (sum of seven 
individual species inclusive of ß-glucosylceramide) elevation was non-discriminatory, but 
concentrations of these compounds were significantly elevated in the cortex and sub-
cortex of mice with neuronopathic Gaucher disease [Figure 2].  With the exception of the 
two longest acyl chain species, 24:0 and 24:1, that remained unchanged [Supplementary 
figure 3], the concentrations of most of the individual monohexosylceraminde species 
were also elevated. For dihexosylceramides (DHC) - the sphingolipid upstream of 
monohexosylceramide in the catabolic pathway- the distribution differed with the longer 
acyl chain species, 22:0, 24:0 and 24:1 significantly elevated in the experimental murine 
brain; in contrast, the shorter acyl chain derivatives, 16:0 and 20:0, were unchanged in the 
brain tissue from mutant animals.  DHC 18:0 co-eluted with sulphatide 24:1 and could 
not be quantified. Trihexosylceramide was not detectable in brain tissue from either wild 
type or homozygous mutant mice with neuronopathic Gaucher disease. 
Of the higher-order gangliosides, a-series species GM3, GM2 and GM1, were all elevated in 
brain tissue from the homozygous mutant mice.  Individual acyl chains of each species 
correlated (Pearson coefficient >0.7), with d18:1/18:0 as the most prominent isoform.  
GM1 ganglioside proved to be the most abundant, and was present at 80-fold the 
concentrations of GM2 and GM3 [Figure 3].  The more complex a-series ganglioside, GD1a, 
was relatively conserved between the subregions of wild type and mutant mouse brain 
tissues, with only the longer chain 22:0 species ubiquitously elevated [Figure 4].  Of the 
b-series, GD3 was more abundant than GD2 but all isoforms of both were significantly 
elevated in both subregions in the brain tissue of the homozygous mutant animals [Figure 
5]. 
DISCUSSION 
Here we report a marked reduction in the cerebral microvasculature volume density (Lvd) 
in a murine model of neuronopathic Gaucher disease. The determinations represent total 
vessel length per cubic micron of tissue and avoid technical bias introduced by the use of 
differing reference volumes [15]. While differences in vascular perfusion and luminal 
patency must be considered, the observed trend in vascular volume proved to be 
consistent in all the mutant diseased animals studied. The methodology employed here 
delineates functional angioarchitecture (vascular perfusion at the point of analysis) and it 
is noteworthy that our results concord with observations reported by Belleri and 
colleaguesin the cognate sphingolipidosis, Krabbe disease, where quantification of  
vascular density employed immunolabelling of vessel endothelium [1, 3]. Indeed, 
detailed studies in the homozygous (galc -/-)  twitcher mouse model of Krabbe disease 
revealed intact spatial distribution of neocortical microvasculature, with a homogeneous 
reduction in total vascular length and increased vessel fragmentation. In their latter 
publications, these authors reported increased intussusceptive angiogenesis with 
upregulated expression of genes integral to this process, suggesting a primary impairment 
of sprouting angiogenesis (a process dependent upon endothelial cytokinesis and cellular 
migration), with compensatory, inflammatory driven, intussusceptive vascularisation; 
attributing this to the accumulation of the psychosine, ß-galactosylsphingosine, a 
substrate with recognised anti-angiogenic properties [3,16]. Our results extend this 
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premise, to the closely related  ß-glucosylsphingosine molecule, which accumulates in 
Gaucher disesase, and is a diastereoisomer form of psychosine, ß-galactosysphingosine. 
We identified a concentration-dependent impairment of endothelial cytokinesis and 
migration upon exposure to pathophysiological concentrations of the substrate, and 
compatible with the disruption of endothelial actin stress fibres also reported on treatment 
with micromolar concentrations of ß-glucosylsphingosine by Belleri and colleagues [1]. 
While a class effect, amongst these related unacylated monohexosylceramide molecules 
is highly probable (and indeed in part revealed by the experiments of Belleri et al), the 
unitary molecular pathways by which these compounds influence angiogenesis are 
unclear;  ß-glucosylsphingosine and ß-galactosylsphingosine stimulate activity of 
phospholipase A2 (PLA2), which in turn generates anti-angiogenic 
lysophosphatidylcholine [5,17-19]. Additionally, these substrates are known to inhibit 
thrombin generation, itself a pro-angiogenic mediator [5].  Indeed, several 
lysosphingolipids, including pro-angiogenic sphingosine-1-phosphate, serve identified 
roles in both developmental and pathological angiogenesis [5,20-25]. In the case of 
sphingosine-1-phosphate, as a ligand of the lysophospholipid G-protein coupled receptor 
subfamily – activation of which induces endothelial cell migration and capillary tube 
formation [26-30]. 
The first clear description of the effect of psychosine on cytokinesis was reported by 
Kanazawa et al [12], with the T-cell death-associated gene 8 (TDAG8), a G-protein-
coupled receptor, implicated as a potential ligand by overexpression studies in 
psychosine-mediated inhibition of cytokinesis [13]. A member of the dual proton-sensing 
ovarian cancer G-protein-coupled receptor (OGR1) subfamily – binding of which has 
been implicated in the dysregulation of actin dynamics [13,24,31-35]. Indeed, it is of 
interest that knock-out models of the GPR4 receptor, another member of this subfamily, 
demonstrate formative abnormalities of vascular networks [36,37]. However, latterly, 
TDAG8 has been reported unequivocally dispensable for psychosine-induced formation 
of multinucleated cells [38] and alternate mechanisms have been implicated, with 
inhibition of cytokinesis by ß-galactosylsphingosine  associated with clustering of 
sphingomyelin at the cell surface, as well as impaired generation of phosphatidylinositol 
4,5-bisphosphate at the cleavage furrow in cultured cells [39]; since both of these steps 
are critical accompaniments of cytokinesis, another cytological explanation for the 
observed multiploidy is available. 
Dyshomeostasis of the complex gangliosides in Gaucher disease has been long-studied 
[11,40,41]: we confirm ubiquitous accumulation of the a-series of gangliosides, GM1, GM2 
and GM3, with GM1 the most abundant, present at 80-fold the concentration of GM2 and 
GM3. Accumulation of the b-series gangliosides, GD2 and GD3, was also evident. 
While a concentration-dependent effect can be suggested for the anti-angiogenic action of 
glucosylsphingosine, this same relationship does not hold true for the complex 
gangliosides where pro-angiogenic compounds GM1, GM2, GD1a and GD3 [4,42-46] 
dominate by volume over gangliosides with suggested anti-angiogenic actions, most 
particularly GM3 [6,42,47,48]. This might be explained by a dominant pathogenic effect 
of glucosylsphingosine – in line with the long held, though incomplete, ‘psychosine 
hypothesis’ of pathogenicity [49]. However, the possibility that wider disruption of lipid 
homeostasis contributes to the phenomena of disordered angiogenesis cannot be 
dismissed, with perturbation of lipid signalling, lipid raft clustering and raft composition 
implicated [43,50]. The latter impacting membrane targeting of proteins integral to the 
regulation of angiogenesis, such as the urokinase plasminogen activator receptor (uPAR), 
a pro-angiogenic mediator, which is preferentially recruited to membrane regions 
enriched with the pro-angiogenic GM1 ganglioside and depleted of anti-angiogenic GM3 
[51]. Increased GM3, relative to total and specific gangliosides is also recognised to impair 
angiogenesis [4,42,48,52-54], while GM3 inhibition of endothelial cell proliferation, 
migration and new vessel formation can be counteracted by the presence of pro-
angiogenic gangliosides including GT1b, GD1a and GD3 [4,42,48]. It is notable that in our 
analyses, the relative concentrations of pro-angiogenic sphingolipids dominate over 
identified anti-angiogenic compounds, raising the possibility of a hierarchy of lipid 
mediated angiogenic regulation, with the pathogenic actions of glucosylsphingosine 
predominant. Indeed, analysis of relative ganglioside ratios within the neuronopathic 
Gaucher model herein, found little difference between the ratios of reportedly pro-
angiogenic gangliosides and anti-angiogenic GM3 [Table 1]; the exception being a relative 
increase in GM2:GM3 in the diseased state, a finding which is superficially incongruent 
with the premise of GM2 as a pro-angiogenic compound, but likely reflects the complex 
contribution of sphingolipids in angiogenic regulation. Tissue specific effects upon 
angiogenesis might also be considered; by example, GD3 is considered pro-angiogenic 
within the cornea and central nervous system [52,55], while reportedly attenuating vessel 
formation within a pancreatic tumour model [56].  
 
 
 
CONCLUSION: 
While perturbations in cerebral angiogenesis does not provide a complete explanation for 
neurodegeneration in Gaucher disease, our reported observations and those in the 
biochemically related Krabbe disease, support contribution of such a mechanism, perhaps 
in part, the result of disturbed actin dynamics [12,13], a premise that warrants further 
attention, with potential for therapeutic modulation of vasculogenesis in these diseases. 
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FIGURES: 
Figure 1. Mean vessel length volume density (Lvd) (µm x10-4/µm3) by anatomical 
subregion: Mean Lvd in wild type control (n = 3) and disease (n = 3) animals within the 
neocortex and thalamus [mean ± SEM & individual mean values displayed]. 
 
 
 
Figure 2. Sub-regional brain glucosylsphingosine (GluSph) and monohexosylceramide 
(MHC):  Concentrations of GluSph are presented as mean ± SEM (A) and total MHC is 
expressed as the sum of the concentrations of seven acyl chain species as the mean ± 
SEM (B) in the cortex and sub-cortex.  Open bars represent WT and filled bars nGD. **p 
<0.01; n=4. 
 
Figure 3. Sub-regional brain monosialated gangliosides GM1, GM2 and GM3: Total 
GM1 is expressed as a sum of the concentrations of d18:1/16:0, d18:1/18:0, d18:1/20:0 
and d18:1/22:0, total GM2 and GM3 each a sum of d18:1/18:0 and d18:1/20:0 (see 
supplementary Table 1 for species measured).  Results are expressed as the mean 
concentration ± SEM in the cortex and sub-cortex.  Open bars represent WT and filled 
bars nGD. **p <0.01, *p <0.05; n=4. 
 
Figure 4. Species of GD1a in the cortex and sub-cortex: Individual species of GD1a are 
presented as the mean concentration ± SEM.  Concentrations of d18:1/18:0 use the right 
hand y axis.  Open bars represent WT and filled bars nGD. **p <0.01, *p <0.05; n=4. 
 
Figure 5. Species of GD2 and GD3 in the cortex and sub-cortex.  Individual species of 
GD2 and GD3 are presented as the mean concentration ± SEM on the left hand and right 
hand y axis, respectively.  Open bars represent WT and filled bars nGD. **p <0.01; n=4. 
 
Table 1. Ganglioside relative concentrations 
 ‘Anti-
angiogenic’ 
 ‘Pro-angiogenic’ 
 GM3  GM1 GM2 GD1a GD2 GD3 
Cortex 
[control] 
 
1.0 : 59.8 0.6 149.0 0.3 1.6 
Cortex 
[Gaucher] 
 
1.0 : 30.8 2.8 86.1 0.4 1.7 
Subcortex 
[control] 
 
1.0 : 78.9 0.9 156.8 0.5 3.9 
Subcortex 
[Gaucher] 
 
1.0 : 55.9 4.6 88.1 0.6 4.7 
Cerebellum 
[control] 
 
1.0 : 38.6 0.8 59.6 0.5 11.0 
Cerebellum 
[Gaucher] 
 
1.0 : 29.6 3.2 43.3 0.7 10.9 
 
Relative concentrations normalised to GM3. 
 
SUPPLEMENTARY FIGURES: 
 
 
Supplementary Figure 1. Percentage multinucleated cells within glucosylsphingosine 
treated human umbilical vein endothelial cell monolayers: Mononucleated, 
binucleated and multinucleated mean percentage cell count, relative to 
glucosylsphingosine treatment concentration (0µM, 5µM, 10µM) at 24 hour and 48 hour 
time points. 
 
 
Supplementary Figure 2. Human umbilical vein endothelial cell monolayer wound 
closure assays: Percentage wound closure within glucosylsphingosine treated human 
umbilical vein endothelial cell (HUVEC) monolayers. (a) wound closure in β-
glucocerebrosidase replete HUVEC monolayer and (b) wound closure in β-
glucocerebrosidase inhibited (cyclphellitol treated) HUVEC monolayer. A concentration 
dependent retardation in wound closure was evident, irrespective of endogenous enzyme 
inhibition with cyclophellitol, upon treatment with escalating concentrations of 
glucosylsphingosine. 
 
 
 
 
Supplementary Figure 3. Acyl chain species of monohexosylceramide (MHC) and 
dihexosylceramide (DHC):  Individual acyl chain MHC and DHC species are presented 
as the mean concentration ± SEM in the cortex and sub-cortex.  Open bars represent WT 
and filled bars nGD. **p <0.01, *p <0.05; n=4. 
 
 
